作者: John D. Pirsch , Elias David-Neto
DOI: 10.1007/978-94-010-1005-4_5
关键词:
摘要: Antimetabolites have been used as adjunctive immunosuppression for renal transplantation since the early 1960s. Azathioprine was one of first antimetabolites to be in chronic protocols having shown effective dogs [1] and subsequently humans [2]. remained a mainstay until mid-1990s when it double-blind randomized trials that mycophenolate mofetil (MMF) had better efficacy prevention acute rejection following [3–5]. Although MMF has replaced azathioprine protocols, many centers still use azathioprine, particularly low-risk patients.